Inventiva (IVEVF) Other Non-Current Assets (2018 - 2025)
Inventiva (IVEVF) posted Other Non-Current Assets of $1.4 million for Q4 2025, up 14.13% on a QoQ basis from $1.2 million in Q2 2025, and up 20.9% year-over-year from $1.1 million in Q4 2024.
Analysis
Inventiva (IVEVF) Other Non-Current Assets (2018 - 2025) Analysis & Trends
Inventiva has reported Other Non-Current Assets for 8 years, with the latest figure at $1.4 million in Q4 2025.
- On a quarterly basis, Other Non-Current Assets rose 20.9% year-over-year to $1.4 million in Q4 2025; TTM through Dec 2025 was $1.4 million, a 20.9% increase from a year earlier, with the FY2025 full-year figure at $1.4 million, up 20.9% from the prior year.
- Other Non-Current Assets was $1.4 million for Q4 2025 at Inventiva, up from $1.2 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $15.7 million in Q2 2024, with the low at $1.1 million in Q4 2024.
- Average Other Non-Current Assets over 5 years is $5.0 million, with a median of $2.8 million recorded in 2021.
- The sharpest annual moves came in 2023 and 2025: Other Non-Current Assets soared 544.12% in 2023, then plunged 92.44% in 2025.
- Over 5 years, Other Non-Current Assets stood at $2.8 million in 2021, then plunged by 39.08% to $1.7 million in 2022, then jumped by 535.72% to $10.8 million in 2023, then tumbled by 89.66% to $1.1 million in 2024, then rose by 20.9% to $1.4 million in 2025.
- The last three Other Non-Current Assets figures came in at $1.4 million (Q4 2025), $1.2 million (Q2 2025), and $1.1 million (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.47 Bn | 624.71 Bn | 17.26 Bn | 14.27 Bn |
| 2 | AbbVie | 439.99 Bn | 433.42 Bn | 12.70 Bn | 10.73 Bn |
| 3 | Merck | 365.45 Bn | 358.31 Bn | 12.21 Bn | 19.60 Bn |
| 4 | Novartis Ag | 266.57 Bn | 258.88 Bn | 11.24 Bn | 5.93 Bn |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn | 9.94 Bn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | 5.50 Bn |
| 7 | Revolution Medicines | 44.23 Bn | 44.23 Bn | - | 42.45 Mn |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | 86.76 Mn |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn | 239.50 Mn |
| 10 | Inventiva | 693.72 Mn | 693.72 Mn | - | 1.35 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 1.35 Mn |
| Jun 30, 2025 | 1.19 Mn |
| Dec 31, 2024 | 1.12 Mn |
| Jun 30, 2024 | 15.67 Mn |
| Dec 31, 2023 | 10.82 Mn |
| Jun 30, 2023 | 11.20 Mn |
| Dec 31, 2022 | 1.70 Mn |
| Jun 30, 2022 | 1.74 Mn |
| Dec 31, 2021 | 2.79 Mn |
| Jun 30, 2021 | 4.15 Mn |
| Mar 31, 2021 | 3.32 Mn |
| Dec 31, 2020 | 2.03 Mn |
| Jun 30, 2020 | 4.56 Mn |
| Dec 31, 2019 | 3.47 Mn |
| Dec 31, 2018 | 2.71 Mn |